Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)

PartnershipPositive

AI Analysis

Summary

Ribo and Boehringer Ingelheim announced achievement of a third key milestone in their research collaboration on a siRNA program for metabolic dysfunction-associated steatohepatitis (MASH).

Outcome Details

Third key milestone achieved in research collaboration

Importance:5/10

Sentiment:

0.50

partnershipsiRNAMASHmetabolic diseasemilestone

Related Companies

$6938

Read the original article

Published by PR Newswire Pharma on May 6, 2026 11:21 AM

Read Original